Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.

@article{Kummar2009Phase0C,
  title={Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies.},
  author={Shivaani Kummar and Robert J. Kinders and M. E. Herrera Guti{\'e}rrez and Larry Rubinstein and Ralph E. Parchment and Lawrence R Phillips and Jiuping Jay Ji and Anne P Monks and Jennifer A. Low and Alice Pei-Jung Chen and Anthony J. Murgo and Jerry M. Collins and Seth Steinberg and Helen Eliopoulos and Vincent L. Giranda and Gary G. Gordon and Lee Helman and Robert H. Wiltrout and Joseph E. Tomaszewski and James H. Doroshow},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 16},
  pages={2705-11}
}
PURPOSE We conducted the first phase 0 clinical trial in oncology of a therapeutic agent under the Exploratory Investigational New Drug Guidance of the US Food and Drug Administration. It was a first-in-human study of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in patients with advanced malignancies. PATIENTS AND METHODS ABT-888 was administered as a single oral dose of 10, 25, or 50 mg to determine the dose range and time course over which ABT-888 inhibits PARP activity in… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

Similar Papers

Loading similar papers…